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In the spring of 2005, a small group of advocates gathered to brainstorm ways 
to improve awareness and advocacy for the research and development of rectal 
microbicides and to magnify their place on the expanding prevention technology 
map. At that time, the silence surrounding rectal microbicides was palpable. 
How could it be that so little was being done to find new ways to make anal 
intercourse safer? After so many years of disease transmission, wasn’t the time to 
scale up rectal microbicide research long over due?
The answer was a loud and resounding yes! The result; the International Rectal 
Microbicide Working Group (irmwg). From that day forward there would be 
an impassioned movement dedicated to strategically advancing our collective 
interest in the promise of rectal microbicides. 
I will take this opportunity to thank those individuals who joined me back in 
2005 to birth this effort:  Anna Forbes of the Global Campaign for Microbicides 
(gcm), Julie Davids of the Community hiv/aids Mobilization Project (champ), 
and Marc-André LeBlanc of the Canadian aids Society (he now runs the Global 
North Programs for gcm). 
While our goal was clear, we didn’t yet have the vision needed to get there.  We 
knew it would be critical to link community advocates with the researchers, 
scientists, policy makers and funders who were doing some incredible, if unnoticed, 
work in the field. We also knew that to be successful we would need to draw on 
the passion and brilliance of people around the world – people who could unlock 
the necessary ideas and resources. 
At the top of our minds, then and now, were the women and men across the 
globe of all sexual persuasions who engage in anal intercourse and desperately 
need new prevention technologies that go beyond latex. 
And here we are, releasing Less Silence, More Science - Advocacy to Make 
Rectal Microbicides a Reality at Microbicides 2008 in New Delhi. Like 
our first publication, released at the Cape Town conference, we hope this new 
document will create visibility, legitimacy and urgency for this cause. We are 
certain this report will propel all of our work forward.
Letter from the chair
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continents
After concluding a process that included our entire membership, we retired our 
old name (irmwg) and are now known by the much more mellifluous, irma 
(International Rectal Microbicide Advocates). Today our membership numbers 
over 500 individuals and organizations from 40 countries on six continents. Our 
web presence has grown from one simple page into an actual website - featuring 
a url that dreams are made of: www.rectalmicrobicides.org.
I know I speak for everyone in our far-flung network when I say I am deeply 
honored to be collaborating with such an incredible array of smart, passionate 
advocates and scientists - you - and am profoundly grateful for the vision and 
financial support of leaders such as Broadway cares/Equity Fights aids, the 
Elton John aids Foundation, the Playboy Foundation, the San Francisco aids 
Foundation, our founding organizations, and all the other organizations and 
individuals who are so vital to our mission and who are duly thanked in this report. 
I would like to extend special thanks to the aids Foundation of Chicago (afc) 
– my home – for such extraordinary support these past three years.
For today, tomorrow, and the day after that, we will continue to advocate 
for more science and an end to the silence that dooms the lives of so many. 
We invite you to join us.
Sincerely,
Jim Pickett
Chair, International Rectal Microbicide Advocates, 
Director of Advocacy, aids Foundation of Chicago
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Introduction
   
Since its creation in 2005, International 
Rectal Microbicide Advocates (irma) has 
seen significant growth and success. From 
a handful of advocates, irma has built 
a network of well over 500 advocates, 
researchers, and policy makers from  
40 countries on six continents. 
New name, new look, same goals
Originally founded as the International Rectal Microbicides Working Group 
(irmwg), the group re-branded our name at the end of 2007, created a new logo, 
and launched a new website (www.rectalmicrobicides.org).  Amidst all this change, 
irma remains committed to the same goals we developed from our inception:
To advocate for accelerated research, development and access to safe, effective and •	
acceptable rectal microbicides;
To promote rectal safety studies on all viable vaginal microbicide candidates;•	
To support, where appropriate, the research of other new prevention technologies, •	
such as male circumcision, vaccines and oral prevention (prep), and to promote 
existing prevention methods such as male and female condoms as part of a range 
of prevention options;
To serve as a central forum for exchange, debate, and networking on rectal •	
microbicides; and, 
To convene diverse perspectives and scientific disciplines to improve understanding •	
and action around rectal microbicide research and development.
Focus on safety
In these very early stages of rectal microbicide development, the primary focus of 
research is safety: examining the rectal safety of sexual lubricants (section 2.12), 
urging the collection of rectal safety data from late stage vaginal microbicide trials 
(section 3.1), determining the measures for assessing basic rectal safety (section 
2.3), and of course, evaluating the safety of potential rectal-specific microbicides 
(sections 2.1 and 2.2).
We hope this document will: 
Serve as an authoritative reference on recent developments and current efforts in •	
rectal microbicide research;
Illustrate key advocacy goals and strategies;•	
Provide a description of the resources and activities of •	 irma; and, 
Inspire people working in •	 hiv prevention, whether in advocacy, research, policy 
or funding, to become involved in rectal microbicide advocacy and research. 
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Clearly, with over 
6,800 
new infections every 
day across the world, 
there is a need to scale 
up global prevention 
efforts significantly
1.1 The global hIv/AIdS pandemic outpaces global 
    prevention efforts
On the eve of  World aids Day in 2007, the Joint United Nations Programme on 
hiv/aids (unaids) announced that over 33 million people were living with hiv 
worldwide, including 2.5 million people newly infected with the virus in 2007. 
Over 2 million people died of aids-related illnesses in 2007.1
No region of the world is spared. Sub-Saharan Africa remains the most affected 
region, where, unlike other areas, the majority of people living with hiv are women 
(61%). The Caribbean remains the second most affected region, proportional to 
its population, and the hiv pandemic continues to grow in Asia, Eastern Europe, 
and Central Asia.2 
There are indications of a re-emerging hiv epidemic among gay men and other 
men who have sex with men (msm) in industrialized countries, including North 
America, Western Europe and Australia. The number of msm reported with hiv 
or aids is now increasing in many countries, including the United States and 
countries of Western Europe.3 
In some regions (Latin America, Australia and New Zealand, North America, 
Western Europe), unprotected sex between men is recognized as an important 
driver of the pandemic.4 In these cases, the majority of infections are likely driven 
by unprotected anal intercourse (uai). But what about sex between men in other 
regions? What about uai between men and women globally? We will address 
these questions in the next section.
Clearly, with over 6,800 new infections every day across the world5, there is a 
need to scale up global prevention efforts significantly. The Global hiv Prevention 
Working Group, convened by the Bill & Melinda Gates Foundation and the 
Henry J. Kaiser Family Foundation, estimates that globally, only 9% of risky sex 
acts are undertaken while using a condom, and that prevention services reach less 
than 10% of men who have sex with men and persons who inject drugs, and less 
than 20% of sex workers.6 
The Working Group calls for massive and urgent scaling up of existing global hiv 
prevention methods. According to the group, “if comprehensive hiv prevention 
were brought to scale, half of the infections projected to occur by 2015 could be 
averted... We could slow and even begin to reverse the trajectory of the global hiv 
epidemic by using the prevention tools currently at our disposal.”7
     
1 Rectal microbicides in context:  the global hIv pandemic,  anal intercourse and human rights
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into the hiv pandemic, 
women and men who  
are the receptive 
partners during anal sex 
still have no prevention 
options they control  
        
       
At the same time, the world desperately 
needs new prevention options that would 
complement existing ones. After more 
than 26 years into the hiv pandemic, 
women and men who are the receptive 
partners during anal sex still have no 
prevention options they control. How 
is silence slowing down the science for 
these needed new tools?
1.2 Criminalization of behaviours and human rights  
     violations: Challenges to a global response to    
     prevent hIv transmission through anal intercourse
At the end of 2007, no less than 85 member states of the United Nations still 
criminalized consensual same sex acts among adults.8 Often called sodomy laws, 
some statutes regulate specific sexual acts (for example, anal sex) regardless of 
gender or sexual orientation while others prohibit a range of same-sex sexual 
activities. Many laws are quite broad in their scope, including the prohibition of 
any “unnatural” or “indecent” sexual act.9
Punishments include fines, imprisonment (from 3 years to life), corporal 
punishment, hard labour, and death.10
In this political climate, it is not surprising that many gay men, other msm, as 
well as women and men who engage in anal intercourse (ai) face significant 
barriers to accessing information and tools needed to protect themselves from 
hiv infection. This is exacerbated by a deplorable dearth of programs and services 
for same-sex practicing people in most developing countries. 
“The vulnerability of same-sex practicing men and women is not due to any biological 
predisposition, but is the result of an interlocking set of human rights violations and 
social inequalities that heighten hiv risk. Anti-gay discrimination is fuelling the African 
hiv/aids epidemic.” 
— International Gay and Lesbian Human Rights Commission. 
Off the Map: How hiv/aids Programming Is Failing Same-sex Practicing People in Africa, 2007.
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Global Coverage for Select HIV Prevention Strategies in 2005
Global HIV Prevention Working Group, 2007; WHO/UNAIDS/UNICEF, 2007
In absolute numbers, 
7 times
heterosexual women 
than gay men in the 
u.s. practice receptive 
anal intercourse
more
1.3 Anal intercourse worldwide:  
     less silence, more science
 
Our knowledge of the incidence, prevalence and context of ai globally is still 
woefully inadequate. However, there is a growing body of literature available. 
Research on ai between men is now more in-depth, and research on ai between 
women and men is increasing.
What we know
Because data collection methods vary tremendously between surveys, broad global 
statements about the incidence and prevalence of ai are currently difficult to make, 
if even possible.
Anal intercourse is a widely practiced behaviour among msm. Among gay men 
in the United States—who are estimated to comprise 2.3%11 to 13%12 of the u.s. 
population—the vast majority (95%) report having engaged in ai.13 Less is known 
about this behaviour among heterosexuals, although ai is increasingly reported.11,14 
While rarely discussed in the scientific literature,15 ai is increasingly understood as a 
more common practice among heterosexuals.  In the u.s. and uk, between 10% and 
35% of heterosexual women report practicing receptive anal intercourse (rai)11, 12, 
16, 17 and lifetime reports of ai with opposite-sex partners are as high as 40% for u.s. 
males.11 In absolute numbers, seven times more heterosexual women than gay men 
in the u.s. practice rai.14 In more specialized study populations, the proportion of 
heterosexuals engaging in anal sex ranges from a high of 32% of sexually active 
women at high risk of hiv exposure in the previous 6 months18 to a low of 23% 
of “non-virgin” university students who reported ever engaging in ai.19 While 
few studies collect data on the incidence of ai between men and women, it seems 
relatively frequent. A household survey revealed that most engaged in this activity 
one to five times per month and 7% of sexually active respondents reported ai at 
least once a month during the year prior to the survey.20 
Anal intercourse between men and women has been linked to an increased 
likelihood of hiv transmission within serodiscordant couples in the u.s.21 and Brazil22 
and has been associated with hiv infection among men and women attending 
sexually transmitted infections (sti) clinics in India.23 This increased risk is likely due 
to greater efficiency of transmission and low frequency of condom use during ai 
between men and women. The unadjusted probability of transmitting hiv is 0.08 per 
contact for rai,24 as compared to 0.001 per coital act for vaginal intercourse.25 This 
is most likely because the lining of the rectum (single columnar epithelium) is both 
more fragile and contains more cd4 cells than the lining of the vagina and part of the 
cervix (stratified squamous epithelium), making it more vulnerable to hiv infection. 
Connections between ai and stis other than hiv are less clear. While ai has been 
associated with gonorrhea in the general population, the relationship has not been 
seen in sti clinic patients.26 Among women, ai has been associated with abnormal 
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anal cytology27, 28 yet little data exist on rectal carriage of other sti pathogens in 
women, largely because female ano-rectal sites are rarely sampled and tested.
Globally, with the exception of communities where condoms are actively promoted 
and accessible for gay men and other msm, almost all ai between women and men, 
as well as between men, is unprotected.29 When women are the receptive partner 
in ai, the power dynamics involved may be different than between two men. For 
example, women may be more prone to engage in anal sex in cultures, contexts and 
regions where virginity is especially prized and contraception not easily accessible.
We must consider the possibility that uai, even when practiced rarely, may in fact 
be a significant source of hiv transmission in many contexts. 
Dangerous silences
Gay men and other msm in North America, Western Europe and other industrial 
countries have made incredible strides in raising awareness, influencing policies 
and advocating for prevention programs that target their disproportionately 
impacted communities. However, all too often the seemingly inseparable 
connection between ai and Western gay and msm has meant critical aspects of the 
pandemic in developing regions are overlooked and under-researched. 
By focusing almost exclusively on gay men, msm, and the West when developing 
policy related to ai in the context of hiv prevention programming, we neglect 
to identify the prevalence of ai between women and men as well as the hiv 
prevalence among, and indeed, the mere existence of, gay men and other msm in 
Asia, Africa and other parts of the developing world. This neglect costs lives. In its 
ground-breaking report Off the Map, the International Gay and Lesbian Human 
Rights Commission decried the wall of silence that surrounds aids and same-sex 
practices in Africa.30 The situation in developing countries outside of Africa is 
often much the same regarding the collective blind eye turned toward msm and 
anal sex practices between women and men.
Precious little research has examined the role of ai in hiv transmission in 
developing countries. However, studies in Senegal, Ghana, Kenya and Sudan 
indicate that rates of hiv prevalence among msm are significantly higher than in 
the general population.31,32 This has also been demonstrated in most countries of 
Latin America, and in several countries and cities in Asia.33,34
The illegality of ai in many countries and jurisdictions, the strong taboo and 
homophobia associated with anal sex, and the imprecise language we use to 
describe populations and behaviours conspire to render these realities invisible. We 
tend to conflate sex acts with identity through the use of  imprecise, misleading 
language. Phrases like “heterosexual transmission” mask the fact that women 
and men who identify as heterosexual engage in ai. This lack of clarity, honesty 
Globally,
 almost 
 all anal 
 intercourse
 is unprotected
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women and men 
who identify as 
heterosexual engage 
in anal intercourse
and specificity negates that a significant portion of the pandemic is likely driven 
by uai in regions broadly characterized as being “driven by heterosexual hiv 
infection.” In this construct, heterosexual hiv transmission automatically translates 
to vaginal intercourse. While identity, sexual orientation and sexual practices may 
be related, they are not always so clearly delineated. “hiv infection via unprotected 
vaginal intercourse” would be a more accurate phrase than “heterosexually 
acquired hiv infection”. 
These are more than innocuous semantics; language matters. Inaccurate language 
impacts quite concretely on program design and delivery; on research design, 
particularly for microbicides; on stigma faced by communities, including gay 
men and other msm; and, on the deceptive absence of other populations that 
engage in ai, including heterosexual men and women, lesbians, and bisexuals 
across the globe. 
What we need to know
In order to improve prevention programs and develop tools that would reduce the 
risk of hiv transmission for women and men who engage in ai, we desperately 
need more research in the following areas:
Standardized incidence and prevalence data on •	 ai between women and 
men, as well as between men, from all regions of the world, including 
developing countries
Greater qualitative data to understand the context for •	 ai across cultures
Improved methods of data collection to maximize confidentiality, and thus the •	
reliability of responses
More information on the behaviours associated with •	 ai, e.g. use of condoms, 
lubricants, douches
Estimates of the role •	 uai plays in the hiv pandemic, including but not limited to 
developing countries, among gay men and other msm in developing countries, and 
among women and men in the context of so-called “heterosexual epidemics”
Mathematical modeling that would assess the potential impact of rectal •	
microbicides on the pandemic, including but not limited to that in developing 
countries, and among various populations, including women and men who 
engage in ai.
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Rectal microbicide research is more robust at the end of 2007 than it has ever 
been. While the world’s first rectal microbicide safety trial is under way, two 
more Phase I trials are in the planning stages. In addition, several research 
projects devoted to rectal microbicide–related topics are ongoing or have 
been recently completed, including projects that seek to establish a pipeline of 
potential products to test as rectal microbicides, to determine which formulations 
might work best rectally, to describe current behaviours and practices related 
to anal sex, to develop applicators and delivery systems that are appropriate for 
rectal use, to establish the baseline parameters that could be assessed in rectal 
trials, to facilitate the regulatory pathway and to establish the rectal safety profile 
of sexual lubricants.
The U-19 Microbicide Development Program (mdp)
While there are several groups that have been advocating and actually undertaking 
preliminary studies of rectal health, rectal toxicity from topical agents like n9, 
rectal physiology and reaction to enemas and receptive sex, there were no 
coordinated efforts to develop rectal microbicides until 2004. In August of 
that year, a 5-year grant from National Institutes of Health’s National Institute 
of Allergy and Infectious Diseases (nih/niaid) was awarded to a consortium 
of researchers and institutions to develop a pipeline for testing the safety 
and efficacy of topical microbicides used rectally. This large grant was funded 
under the nih’s unique Integrated Preclinical/Clinical Program (ipcp), designed 
to support innovative, important translational research (bench to bedside, as it 
were). The primary site for this award was ucla with collaborative institutions 
(and lead researchers) of Johns Hopkins University, University of  Washington in 
Seattle, nih itself, University of Pittsburgh/Magee Women’s Research Institute, 
St. George’s Hospital and Medical School in London and the Health Protection 
Agency at Porton Down (near London).  
The grant has five projects which approach the rectal microbicide issue from 
different angles and are coordinated to feed their derived data and information 
into each other to make the final whole greater than the parts. The projects are 
(i) preclinical and macaque trials which look at different compounds for safety 
in the cells line and then in the explant system. Then, with favourable agents, 
evaluate safety and possible efficacy in non-human primates; (ii) a novel trial 
involving nearly 900 participants in Baltimore and la to identify behavioural 
perceptions, symptoms and signs associated with rectal health, in general, and 
what might be associated with rai in men and women, hiv-negative and 
hiv-positive. This trial will have a subset of volunteers testing different potential 
applicators or “carriers” of rectal microbicide drugs to see what form they would 
find more acceptable when the real manufacturing process begins; (iii) a group 
2 The state of rectal microbicide research    
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In early
began actively 
enrolling for the 
world’s first rectal 
microbicide 
safety trial
that is focused on developing formulations or carriers that will hold the rectal 
microbicide drugs, that will be designed specifically for the rectal compartment 
(in contrast to trying to adapt vaginally-formulated products); (iv) human trials of 
the effects of different kinds of enemas on causing injury to the fragile lining of 
the rectum and conduct tests designed to identify where the new rectal-specific 
formulations might actually distribute in real life; and finally, (v) two human 
Phase I trials of vaginally-formulated microbicides used rectally. These are the 
first true rectal microbicide Phase I trials.
As indicated by an asterisk (*), the following sections are part of this u-19 
Microbicide Development Program: sections 2.1, 2.3, 2.4, 2.5, 2.6, 2.7 and 2.10.
2.1 The world’s first rectal microbicide safety trial:  
     testing UC-781*
In early 2007, the University of California, Los Angeles (ucla) began actively 
enrolling for the world’s first rectal microbicide safety trial. This is a Phase I 
randomized, blinded, placebo-controlled safety and acceptability study of the 
uc-781 vaginal microbicide gel formulation applied rectally in hiv-1 seronegative 
adults.35
The trial is sponsored by conrad in partnership with the nih/niaid.
Participants are exposed to either one of two concentrations of uc-781, a 
non-nucleoside reverse transcriptase inhibitor (nnrti) or a placebo, in a single 
dose followed later by a 7-day exposure. The uc-781 gels and the universal 
placebo gel are the same as in vaginal trials.
The trial objectives are:
To evaluate the safety and acceptability of 0.1% and 0.25% •	 uc-781 vaginal 
microbicide gel versus placebo when applied rectally.
To determine whether use is associated with rectal mucosal damage. •	
To determine the pharmacokinetics of •	 uc-781 vaginal gel administered rectally 
in a subset of participants. This will help to guide future trials by providing an 
indication of how much drug is absorbed, and give further guidance when 
planning a trial among hiv-positive participants to measure potential resistance.
There are 36 hiv-negative men and women with a history of rai participating in 
the study, divided into the three arms. Six of them are part of the pharmacokinetics 
study. Over a period of eight weeks, participants have five visits to the clinical trial 
site. This includes three flexible sigmoidoscopic exams, a procedure that involves 
placing a tube about the size of a finger (with light, water and air sources) into the 
rectum to visually examine and collect small amounts of tissue (biopsy) through 
2007 
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a channel in the scope. This is the same exam that, in the past, was recommended 
for all people for colon cancer screening. Biopsy samples are taken at 10 and 30 
cm from the anal opening. 
In contrast to biopsies taken from skin (or other areas that have nerve endings that 
detect pain), the inner lining of the gut/intestines does not have these pain nerve 
endings. So, biopsies are not really felt nor are they painful to obtain. Sometimes, 
a fair amount of air can be used in order to “open up” the colon enough for the 
scope to be slowly advanced. This distends the intestine, like when one has to pass 
gas, and can feel “uncomfortable”. But it is very rarely painful in someone who 
does not otherwise have an underlying disease process in the gut. 
In addition, throughout the trial, subjects also undergo testing for hiv, a range of 
stis and pregnancy as well as standard measures of safety such as Complete Blood 
Cell counts and chemistry panels. Stool samples and rectal secretion samples are 
also taken for research testing.
The trial includes several dozen tests and evaluations of safety, pharmacokinetics 
and acceptability, including:
Epithelial sloughing – this determines if the product causes the surface of the •	
mucosa to separate from the tissue.  
Histopathology – a microscopic review of the tissue to see if the product causes •	
physical changes.
Mucosal mononuclear cell phenotype (flow) – this tests whether the product •	
changes the types or amounts of cells (cd4s, cd8s, other) or how activated 
(“turned on”) they are in the mucosal tissue.
Mucosal cytokine m•	 rna (tissue) – Mucosal cytokine/chemokine expression 
(substances linked to tissue inflammation) will be measured using the polymerase 
chain reaction (pcr) technique.
Mucosal immunoglobulins – this measures possible changes in the levels of •	
secreted antibodies the body sends into the gut area – an injurious drug might 
impact these protective levels.  
Fecal calprotectin – a measure of gut mucosal inflammation. •	
Explant susceptibility to •	 hiv infection – these are tests run on small pieces of 
mucosal tissue from the subjects to see if the product has an effect on the growth 
of hiv put on the tissue in the lab. It is hoped that the investigation might show 
that when the subject’s biopsies have been exposed to the microbicide in vivo (in 
real life), the drug will also demonstrate inhibition of viral replication in the lab 
in the tissue (ex vivo).  
uc-•	 781 blood levels to determine absorption from the gastrointestinal tract – 
this will give an indication of how easily this drug gets through and is absorbed 
into the blood for distribution to the rest of the body.
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Behavioural questionnaire – this is a computer based survey of the sexual health •	
and history of participants. 
Product acceptability questionnaire – this is a computer based survey of how •	
people felt about the applicator and gel used in this particular trial.
Acceptability interview – after completion of the trial, subjects complete an in •	
depth interview including open ended questions about the product and applicator, 
future possible use of a microbicide as well as issues related to participation in 
the trial.
Some of the challenges to testing products rectally include dealing with fragile 
epithelia – single cell-layer thick – which can potentially be damaged through 
some of the study-related actions and tests themselves, such as the product 
applicator itself. This obviously poses significant challenges to measuring safety 
of the product being tested. In addition, rectal mucosa has increased absorptive 
potential and therefore potentially increased resistance profiles, compared to 
genital mucosa. It is a well-known and frequently used route of delivery of 
medications when patients can not take medications orally. Therefore, systemic 
(body) absorption of these topically applied products needs to be carefully 
considered. A number of the research parameters remain untested or unproven, 
including the safety indices for healthy subjects, and the suspicion that there are 
gender differences. This trial includes the most extensive list of rectal safety and 
mucosal immunotoxicity and mucosal injury measure yet utilized in a clinical 
trial in healthy subjects. It is hoped that results from this trial will help refine the 
list of necessary assays for future trials.
Results from the trial are expected in late 2008.
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2.2 Upcoming rectal microbicide safety trials:  
     testing PRO 2000 and vivaGel for rectal safety 
Two additional Phase I rectal safety studies are currently being planned for 2008. 
 
The first study will evaluate the rectal safety of the vaginal formulation of 
VivaGel®. VivaGel is a polyanion dendrimer microbicide being developed by 
Starpharma Pty Ltd, an Australian biotechnology company. The product has 
already been studied in one Phase I vaginal safety study and two additional 
vaginal Phase I studies are currently ongoing. In addition, a penile tolerance study 
has been completed. A rectal safety study has already been conducted in monkeys 
and the 3% strength product seemed well tolerated. The rectal safety study will be 
conducted at ucla and the University of Pittsburgh and is hoped to start in 2008. 
Enrolment will include hiv negative sexually abstinent men and women who 
have a history of practicing anal sex. This study will be sponsored by the Sexually 
Transmitted Infection – Clinical Trials Group that is sponsored by the nih.
The second rectal safety study will be conducted on the other side of the 
Atlantic and is being sponsored by the United Kingdom Medical Research 
Council Microbicide Development Program (mrc-mdp). This study will 
evaluate the rectal safety profile of pro 2000 (0.5% and 2%) in sexually 
active msm. pro 2000 is a polyanion microbicide being developed by Indevus 
Pharmaceuticals Inc in the u.s. The study will sequentially enrol hiv-negative 
and then hiv-positive msm. The two concentrations of pro 2000 are currently 
being evaluated as vaginal microbicides in a large Phase III effectiveness study 
being conducted in sub-Saharan Africa. The mrc-mdp hopes to start this 
trial in 2008.
2.3 Establishing baseline mucosal measures  
      for rectal microbicide trials*
A critical question in rectal safety trials design is deciding what to measure. In 
late 2007, Dr. Ian McGowan and his team from ucla published the results from a 
study that established, for the first time, the most stable parameters that could be 
used in studies of candidate microbicides used rectally. The study is published 
in the December 2007 edition of the Journal of Acquired Immune Deficiency 
Syndromes.36 
Microbicide developers need to have a precise set of baseline measurements so 
they can accurately assess the impact of candidate microbicides in the rectum. 
Until now, without this baseline that describes what is “normal” in the absence of 
a candidate microbicide, a standardized comparison was not feasible. For example, 
the measures will help to assess the level of inflammation and cytotoxicity 
(cell-killing properties) caused by candidate microbicides.
This set of baseline measurements has already been done in vaginal and cervical 
tissues. They now exist for the rectum, which will allow for more standardized 
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testing, and improved comparability between rectal safety studies. This includes 
assessing the rectal safety of vaginal microbicides and rectal-specific microbicides 
once they are developed.
Sixteen volunteers participated in the study: four hiv-negative men who had 
been having (protected) ai at least once a week; four hiv-negative men who had 
not had ai for at least two months; four hiv-positive men not on antiretrovirals; 
and four hiv-positive men on antiretroviral drugs (arvs) with viral loads under 
50. All the hiv-positive men recorded having ai, protected or otherwise. 
The volunteers were described by the researchers as “dedicated” because the 
study involved taking 20 tissue biopsies from two different sites, ten at each site, 
10cm and 30cm from the anal entrance, three times within a month. (See section 
2.1 for a description of this procedure, and an explanation for why it is not 
painful.) They also took samples of rectal secretions. 
The team then evaluated the samples for signs of inflammation and immune 
response. There was almost no evidence of overt inflammation in any subject, 
which seems to indicate that ai in itself does not produce inflammation (men 
with conditions like diarrhea, herpes, gonorrhea and chlamydia that would cause 
inflammation were excluded from the study). However, different people seem to 
have different base levels of inflammation and immune responses, so measuring 
the impact of a candidate microbicide may be difficult without knowing these 
base levels.
The key findings of the study included recognizing that the level T cells and 
cytokines (inflammatory proteins often released by T cells) in the mucosa 
remained relatively stable from visit to visit. This is important as changes in T cell 
or cytokines induced by microbicides might make participants more vulnerable 
to hiv infection. Scientists can now use these data to track changes in rectal 
mucosa associated with microbicide application. Another useful observation was 
that there didn’t seem to be much difference between tissue collected at 10cm 
and 30cm. This allows investigators to focus on sampling tissue at 10cm – an 
important step in reducing the complexity of rectal safety studies.
Future research in this area should include a larger number of participants as well 
as women, for whom results may be different.
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2.4 Regulatory compliance in microbicide trials* 
The regulatory issues faced by institutions performing clinical research have 
become increasingly more complex, placing greater demands on investigators for 
timely and complete compliance to federal and institutional guidelines. While 
regulatory approval helps ensure trials are conducted ethically, many investigators 
do not have an expert on staff that understands the regulatory issues involved 
in managing investigational research and the institution’s obligations under the 
federal rules. 
As part of the u-19 program a Regulatory Compliance and Subject Safety Core 
was created which provides an infrastructure of regulatory and technical expertise 
to facilitate management of and to maintain compliance with the regulatory 
responsibilities of the u-19 Projects while acting in an efficient and cost effective 
manner to facilitate conducting the clinical trial aspects of the three projects in 
the mdp, including the Phase I rectal microbicide safety trial. This is emerging as 
a standard structural component of any complex translational program involving 
human tissue samples. 
2.5 Preclinical evaluation of hiv rectal  
     microbicide candidates*
Through the u-19 Microbicide Development Program (mdp) centered at ucla, 
Dr. Ian McGowan and collaborators at St. Georges Hospital and Medical School 
(headed by Dr. Robin Shattock) and Health Protection Authority, Porton Down 
(headed by Dr. Martin Cranage) propose to establish a pipeline for the preclinical 
development of highly active and safe microbicides to prevent rectal transmission 
of hiv infection. The project has four overall goals:
Aim 1 of this project is to define potential mucosal target cells for hiv infection 
and to characterize dissemination of migratory cells, with the potential to carry 
hiv, from rectal mucosa to other lymphoid tissue reservoirs. 
Aim 2 will be to evaluate the efficacy of potential rectal microbicide candidates, 
alone and in combination against hiv infection using cell-based assays and explant 
cultures. Initial studies will focus on the three antiretroviral reverse transcriptase 
inhibitor (RT) compounds: pmpa, uc-781 and tmc-120 alone and when 
formulated as gels. 
Aim 3 will be to evaluate the tissue biocompatibility of these rectal microbicide 
candidates, alone, and in combination, using cell based assays and intestinal explant 
cultures. 
Aim 4 will be to evaluate the efficacy of candidate rectal microbicides against 
rectal challenge with siv (in the case of pmpa) and infectious rt-shiv (in the 
case of uc-781 and tmc-120) in the Rhesus macaque model of siv/rt-shiv 
infection. 
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These aims will distill and establish preclinical steps in rectal microbicide drug 
development which will then transition to exploratory safety evaluation of the 
same compounds in human studies. 
2.6 Aptamer microbicide development program*
The aptamer microbicide development program is a unique collaboration 
between the University of Pittsburgh, the University of Oxford, uk, and a Belgian 
biotechnology company. The primary goal of the study is to develop aptamers 
with specific activity against viral stis including hiv, hsv, and hpv. 
Aptamers are sequences of nucleic acid that are specifically generated to bind to 
and hopefully render inactive viral targets. Randomly generated sequences of rna 
are washed over fragments of the relevant viruses. rna sequences that are shown 
to bind to the viral targets can then be captured and synthesized in sufficient 
quantities to allow evaluation of their activity in cell culture and tissue explant 
systems.  
This program is currently focusing on generating hiv specific aptamers and 
evaluating them in anal, rectal, and cervical hiv infection studies. Theoretically, 
it might be possible to generate a multifunctional antiviral aptamer microbicide 
that might have activity against hiv, hsv, and hpv in rectal and cervical tissue. One 
of the challenges of working with rna aptamers will be to modify the rna so 
that it is stable in the rather hostile environment of the rectum and vagina. 
2.7 Assessing rectal microbicide formulations*
Development of an effective rectal microbicide could be greatly enhanced by 
knowledge of the distribution of hiv in the rectum and into the surrounding 
tissues following sexual exposure, as well as the duration of the presence of hiv 
in these areas. Armed with this information, one could optimize the design of 
microbicides so that they outdistance and outlast hiv. It would also be beneficial 
to be able to measure the toxicity of a microbicide candidate, including toxicity 
duration. Advances in research have given us the ability to evaluate the effects 
of various formulations and active ingredients in much more sophisticated 
ways.  Therefore we have the ability to move forward in attempts to define 
compartment-specific, mucosal-surface friendly and safe formulations in advance 
of broad clinical testing for efficacy. 
A group of scientists from the mdp have developed methods to measure the 
distribution of products (gels and liquids) put into the rectum, simulate receptive 
ai, and to follow the movement of these products over time. They have applied 
these methods to study the luminal and tissue distribution of surrogates for 
cell-free and cell-associated hiv. Combining these methods, one can study the 
distribution of microbicide candidates simultaneously with the distribution of 
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hiv surrogates. This information can be used to evaluate the adequacy of the 
microbicide distribution. These methods are being used in two related mdp studies 
– one study focuses on different kinds of enemas and the other is evaluating 
different kinds of gels.
It is important to better understand enemas because studies have shown that 
they are commonly used prior to ai (see section 2.11). Some kinds of enemas, 
including tap water enemas, have been shown to disrupt the lining of the rectum. 
Sexual lubricants are even more commonly used but less well studied. Like 
enemas, commonly used over-the-counter sexual lubricant gels may also disrupt 
the rectal lining (see section 2.12). Accordingly, both enemas and lubricants may 
contribute to the risk of hiv infection associated with ai. Conversely, because these 
products are so commonly used in association with ai, they could be excellent 
candidates for a microbicide drug delivery method if non-toxic enemas and gels 
could be developed. Therefore, if these formulations could be used to deliver 
effective microbicides, their implementation could involve little or no behaviour 
change. Rather, it would only involve a change in product selection, possibly at 
minimal additional cost.
In each of the mdp studies, the distribution over time of the enemas and gels 
is being studied to understand their suitability as microbicide delivery devices. 
This can be judged by comparisons of distribution with enema or gel and hiv 
surrogates. In addition, the rectal mucosa will be evaluated with several sensitive 
measures of toxicity to assess which enema or gel has the least effect on the 
health of the rectal lining and which may enhance hiv transmission. Finally, the 
acceptability of these enema and gel products is being extensively evaluated. The 
scientists believe that the combination of distribution, toxicity, and acceptability 
information will better inform the rational design of a rectal microbicide designed 
specifically for rectal application.  
The enema comparison study was already underway in late 2007.  
The gel study will begin in the second half of 2008.
2.8 Rectal microbicide formulation preference trial 
Gels and suppositories are two possible rectal microbicide delivery vehicles. 
Through a rectal microbicide formulation preference trial funded by the National 
Institute for Child Health and Human Development, Dr. Alex Carballo-Diéguez 
explored user preferences. 
The trial recruited 77 hiv-negative msm who reported a recent history of 
inconsistent (or no) condom use for rai to compare a placebo gel (35ml) 
delivered intrarectally with placebo rectal suppository (8g). The trial consisted 
of a cross over design in which men rated their product preferences after being 
assigned to use the gel in up to three occasions of rai, and subsequently to use the 
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suppository in up to three occasions of rai; or, alternatively, to try the suppository 
first and the gel second. 
The results of the trial showed that more participants preferred the gel over 
the suppository (75% vs. 25%, p <.001), and so did their partners (71% vs. 29%, 
p <.001), according to the participants’ report. Paired t-tests comparing gel 
vs. suppository showed more favorable ratings for the gel overall and also on 
attributes such as color, smell, consistency, feeling in rectum immediately after 
insertion and/or 30 minutes after insertion, and application process. 
The gel resulted in less negative ratings than the suppository in terms of 
participants being bothered by leakage, soiling, bloating, gassiness, stomach 
cramps, urge to have bowel movement, diarrhea, pain or trauma. Participants also 
scored the gel more favorable than the suppository in terms of feelings during 
ai, sexual satisfaction using the product, partners’ sexual satisfaction, liking the 
product when condoms were used and when condoms were not used. 
Participants indicated a higher likelihood to use the gel than the suppository in the 
future if it were found to provide some benefit against acquiring hiv infection.
2.9 Rectal microbicide delivery device study 
In January 2007, Dr. Alex Carballo-Diéguez received support from the American 
Foundation for aids Research (amfar) to conduct a study in collaboration with 
path to develop a prototype of an inexpensive standard rectal microbicide delivery 
device (mdd) that could be used across rectal microbicide trials to ensure ease of 
use, comfort, and effective delivery of microbicide gel across a wide range of dose 
volumes to both men and women who have ai. 
Prior studies had demonstrated that the applicator used to deliver a rectal gel was 
a crucial factor influencing rectal microbicide acceptability.
Following interviews with the nine experts in the field of rectal microbicide 
development (including irma members), specifications of a mdd were developed 
and sent to prospective manufacturers. At the time of this writing, manufacturers 
had bid to obtain the contract for the production of an mdd prototype and the 
contract was awarded to hti Plastics. They have shared with Dr. Carballo-Diéguez’s 
team an initial three-dimensional model and a final version was in development, 
with anticipated completion in the months ahead.
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2.10 Establishing rates of ano-rectal symptoms  
       and signs among men and women who  
       practice receptive anal intercourse*
As part of the U-19 mdp, Dr. Pamina Gorbach is leading a large epidemiological 
study of rectal health and behaviour among 896 men and women in Los Angeles 
and Baltimore to establish the prevalence of ano-rectal health conditions and 
practices. Half of this sample (450 individuals) will have recently practiced rai. 
The sample will also be half hiv-positive individuals. All study participants are 
completing an extensive interview about the ano-rectal symptoms they are 
currently experiencing, their sexual behaviour including use of commercial 
lubricants and specific practices that occur along with rai, and their practice 
of anal hygiene behaviours (including use of enemas, rectal douches, and high 
colonics). All study participants are then tested for stis, and examined by a 
clinician and clinical signs recorded with a high resolution anoscope. 
The findings of this study will establish prevalence of ano-rectal symptoms and 
disease and assess the relationship of sexual practices to ano-rectal symptoms 
and clinical diagnoses, including infections among 896 women and men before 
the introduction of study products such as rectal microbicides or placebos. This 
will help with the interpretation of reported ano-rectal symptoms and observed 
clinical signs in clinical trials of rectal microbicides. The findings from this study 
will serve as baseline measures of anal health to compare during clinical trials 
when randomization will be product vs. placebo.  The study is expected to be 
completed by July 2009; it was one-third enrolled at the end of 2007. 
2.11 The use of rectal douches among men  
       who have anal intercourse 
For hiv-negative men, douching may result in rectal mucosal damage that may 
facilitate the entry of hiv or other pathogens. In the case of hiv-positive men, 
whether rectal douching may exacerbate viral shedding needs to be investigated.
In a study from the hiv Center for Clinical and Behavioral Studies (u.s.)37, 
researchers interviewed men who use the Internet to meet other men for 
intentional condomless ai  (“bareback”).38,39 This study had three objectives. First, 
to report the prevalence of douching behaviours in a sample of men at high risk 
for hiv transmission. Second, to analyze whether rectal douching behaviour (e.g., 
age of onset, douching frequency, and number of pre-coital douching occasions) 
varied significantly by demographic characteristics (as had been reported for 
vaginal douching) and hiv status. Finally, to test whether pre-coital douching was 
associated with positive hiv status after controlling for unprotected receptive anal 
intercourse (urai) occasions.
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A multiethnic sample with overrepresentation of hiv-negative msm who had urai 
in the previous year was recruited exclusively through the Internet. Participants 
were 105 msm (78 hiv-negative, 27 hiv-positive). 
A total of 53% of hiv-negative and 96% of hiv-positive men douched in preparation 
for sex, most of them frequently or always, mainly for hygienic purposes. 27% of 
hiv-negative and 44% of hiv-positive douched after sex, partly believing douching 
protected from infections. Douching practices started around age 25. 
Regression analyses found the association between hiv status and douching 
occasions persisted after controlling for demographic characteristics and number 
of urai occasions. Rectal douching in preparation for sex is common among men 
who practice urai. This population could benefit from alternatives to condoms, 
such as rectal microbicides. Given the popularity of pre-coital douching and its 
frequency, a harmless rectal douche that could deliver a rectal microbicide could 
have great acceptability.
Given that respondents practice rectal douching as a hygiene measure prior to sex, 
and considering the frequency with which the behaviour takes place, it is likely 
to be quite resistant to change, as has been reported to be the case among women 
who use vaginal douches. Furthermore, the association between douching and 
hiv-positive status that persists after controlling for number of urai occasions 
highlights the need to pay attention to rectal douching as a possible contributing 
factor to hiv transmission.
However, not all rectal douches may have harmful effects. One study did not 
observe epithelium loss after peg-es enemas.40 Therefore, it may be possible to 
develop products that achieve the hygienic purpose pursued by users while 
avoiding harmful effects.41 Furthermore, if a harmless rectal douche could be 
used as the vehicle to deliver an effective microbicidal agent, it could be possible 
to achieve wide coverage of the rectal mucosa with a protective agent prior to 
intercourse. A douche that was expelled or absorbed by the mucosa while leaving 
the microbicidal agent in any place that may become exposed to hiv during or 
after intercourse could be more acceptable than the current gel formulations of 
microbicides which may require a significant volume of gel to be present in the 
rectum during intercourse.42
Rectal douching after sex also merits attention, given that it is reported by a 
quarter of uninfected men and almost half of those infected. Would post-coital 
douching wash away a microbicide while ineffectively removing pathogens? 
Future research in microbicide development should consider the formulation 
of a multipurpose product that can be effectively used as a microbicidal and as 
a douche, not only before, but also after sex. Alternatively, future behavioural 
prevention interventions among msm should consider incorporating cautionary 
information about the potential harms associated with douching after sex. 
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Rectal douching may increase the susceptibility to hiv and other sexually 
-transmitted infections by sloughing the anal epithelium.43 As a prime population 
to benefit from the availability of hiv prevention alternatives to condoms, such as 
rectal microbicides, it is vital to decrease sexual hygiene practices that may render 
the microbicide ineffective. For example, a potential harm reduction approach 
to minimize the sloughing of the anal epithelium may be to inform msm on the 
risks of using soapsuds and water enemas and/or to increase the accessibility and 
marketing of peg-es enemas.44
Future studies exploring what hygienic practices precede or follow ai and the 
effect that they may have on the action of a microbicide are necessary.
2.12 Assessing rectal safety of sexual lubricants 
The connective tissue of the rectum is protected by a single layer of epithelial 
cells. Lymphocytes and macrophages, potential target cells for hiv, reside in this 
connective tissue. There is overwhelming evidence that a break in the epithelium 
provides a conduit for hiv to make contact with target cells in the connective 
tissue. Breaches in the epithelium can therefore increase the risk of hiv infection. 
Unfortunately, rectal tissue is so fragile that the epithelium can be breached 
relatively easily. Thus, if a microbicide or sexual lubricant were to cause trauma 
during ai, it could increase susceptibility to hiv infection. As many men and 
women use sexual lubricants during ai, it is important to assess their safety for 
rectal use and to advise people about their relative safety. Determining the safety 
of sexual lubricants is not an easy task. 
There are hundreds of different sexual lubricants available on the market. In 
addition to these, other substances are used as sexual lubricants, especially in 
the developing world where people cannot afford to purchase sexual lubricants. 
Given that clinical studies of rectal safety are expensive, time consuming and can 
only be conducted by a few expert clinicians, a clinical study of all products is 
impractical. In addition, clinical assessments were developed to identify major 
problems, and thus, these assays may not be sufficiently sensitive to detect minor 
breaches in the epithelium.
The Population Council has employed in vitro and mouse assays to determine 
the safety of sexual lubricants. The advantage of these assays over clinical studies 
is that they are far less time consuming and expensive so a number of lubricants 
or microbicides can be examined relatively easily. Although the assays can be 
done relatively fast, it is not possible to determine how relevant the assays are 
to what actually happens during ai. Also, as is the case with clinical assays, it is 
not clear if the methodology is sensitive enough to detect minor trauma.
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Three assays are used to study rectal safety at the Population Council. The first 
is a simple cytotoxicity assay where they study the concentration of a lubricant 
that causes cell death in human colorectal cells in vitro. The second is a mouse 
infection assay. Although mice are not susceptible to hiv infection, they can be 
infected with herpes simplex virus 2 (hsv-2) following rectal administration. 
The third assay involves counting the number of epithelial cells that are sloughed 
following rectal administration of a lubricant in mice. The Population Council 
developed this assay because they previously observed that products containing 
Nonoxynol-9, which enhance hsv-2 infection, also cause sloughing of the 
epithelial cells lining the rectum.
So far, the Population Council has used these assays to study four different sexual 
lubricants. Two of the lubricants, ky Plus and delube (now off the market) were 
considerably more cytotoxic, caused more cell sloughing and enhanced hsv 
infection as compared to saline controls.45 They are currently using these assays 
to study additional sexual lubricants and are hopeful that their findings will help 
advise users which lubricants may be safest for use during rectal intercourse. 
irma continues to monitor this research and to urge timely dissemination of the results.
2.13 Collecting data on rectal use of products and  
      anal intercourse in vaginal microbicide trials
Currently, most vaginal microbicides trials collect behavioural data by asking 
participants whether they have engaged in ai. This information can be an 
important component of determining the reliability of trial results, and help to 
identify potential safety concerns related to rectal use of the products. However, 
the type of data collected varies greatly from trial to trial.
First, various trials ask questions at the point of screening, at enrolment and/or 
during follow-up visits in the course of the trial.
Second, depending on the trial, participants are asked about ai in a variety of 
ways. This can include whether they have ever engaged in ai, whether they have 
ever engaged in uai, whether they have engaged in either unprotected oral or 
anal sex, whether they used a condom the last time they had ai, or the frequency 
in which condoms were used when having ai.
Third, the time frame used in the questions about ai also varies greatly, ranging 
from whether they ever engage in ai, or in the past week, in the past 4 weeks, in the 
past 30 days, in the past 3 months or since their last visit, depending on the trial.
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Obviously, the data collected vary considerably, making comparisons between 
trials difficult.
Participants are counselled against using the product rectally, since it has not been 
designed or tested for rectal safety. However, in some cases, participants may still 
use the product for ai. In these cases, gathering information on rectal use may 
help to identify any potentially serious adverse events. 
In trials where candidate vaginal microbicides do not prove efficacious, gathering 
information on ai could allow researchers to identify uai as a possible factor in 
cases where, despite randomization, one trial arm has higher rates of ai than 
another.
2.14 Biomedical, social and behavioural research  
       funded by amfAR 
amfar, The Foundation for aids Research, is one of the world’s leading nonprofit 
organizations dedicated to the support of aids research, hiv prevention, treatment 
education, and the advocacy of sound aids-related public policy. Since its 
founding in 1985, amfar has been associated with important hiv/aids research, 
having invested nearly $250 million in its programs and awarding grants to more 
than 2,000 research teams worldwide.
In early 2007, amfar awarded nearly $1 million to eight research projects aimed 
at increasing understanding and prevention of rectal hiv transmission.
The 8 projects are:
Development of a standard rectal microbicide delivery device1.   
Dr. Alex Carballo-Dieguez  
Research Foundation for Mental Hygiene, Inc. (u.s.)
Social Networks and their role in 2. hiv transmission between  
Chinese msm and Women  
Dr. Hongjie Liu  
Wayne State University (u.s.)
Exploring epithelial injury in regions of the rectum and colon  3. 
most susceptible to hiv infection following intercourse  
Dr. Craig Hendrix  
Johns Hopkins University School of Medicine (u.s.)
Anal sex practices among South African women and men4.    
Dr. Joanne Mantell 
Research Foundation for Mental Hygiene, Inc. (u.s.)
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Bridget Haire
irma Steering Committee  
Australian Federation of  
aids organizations (Australia) 
“Microbicides, which are 
designed for receptive 
partners, could put power 
into the hands (and 
rectums and vaginas)  
of those who tend to  
be disempowered.”
Rectal transmission of 5. hiv-1 in genetically engineered mice  
with an immune system that mimics that of humans   
Dr. Roberto Speck  
University Hospital of Zurich, Zurich (Switzerland)
Colorectal responses to 6. hiv-1 and modulation by microbicides 
Dr. Carolina Herrera and Dr. Robin Shattock 
St. George’s University of London (uk)
Anal intercourse, 7. stis, and hiv among men who have sex with men and women  
Dr. Marjan Javanbakht, Dr. Peter Anton and Dr. Pamina Gorbach  
University of California, Los Angeles (u.s.) 
Understanding how 8. hiv and rectal cells interact at the point of infection  
Dr. Charlene Dezutti 
Magee-Women’s Research Institute and Foundation (u.s.)
 
“While support for the development of vaginal microbicides has thankfully grown over the 
past few years, these amfaR grants will help fill the persistent gaps in our understanding of 
rectal hiv transmission. They will help us understand how to formulate and deliver a rectal 
microbicide that can and will be used by diverse populations around the world who are at 
risk of rectal hiv transmission.” 
— Dr. Rowena Johnston, 
Vice President, Resarch,amfaR
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Dr. Peter Anton
ucla (u.s.)
“This work is so 
incredibly important. 
Every day we don’t move 
forward, thousands more 
get infected. There is an 
ethical obligation here 
to advance the research 
and development of 
rectal microbicides, 
with good science and 
community awareness.”
irma activities are underpinned by a highly active, moderated global listserv, a 
website (www.rectalmicrobicides.org) featuring a wealth of information and 
resources, and regular teleconferences hosted by member organizations featuring 
presentations on cutting-edge rectal microbicide science. Ongoing advocacy 
includes mobilizing on issues such as the rectal safety of candidate vaginal 
microbicides and responding to false claims. Throughout most of 2007, the group 
developed, disseminated, and analyzed an international internet-based survey on 
lubricants used for ai (section 3.2).
3.1 Consensus statement on rectal safety 
of candidate vaginal microbicides 
In May 2007, irma issued a statement calling upon the microbicide community 
to support rectal safety trials of candidate vaginal microbicides which have 
progressed to Phase iii efficacy trials. 
irma strongly supports the collection of rectal safety data for all candidate vaginal 
microbicides in efficacy trials to ensure information is provided to eventual users 
through appropriate product labelling and community education efforts.
The statement was endorsed by the African Microbicides Advocacy Group (amag), 
the Alliance for Microbicide Development (amd) and the Global Campaign for 
Microbicides (gcm).
Specifically the statement urges:
Trial sponsors to fund rectal safety trials alongside all candidate vaginal 1. 
    microbicides in efficacy trials;
Donors to provide more resources for the field to conduct rectal safety trials; 2. 
Regulatory agencies to provide guidance describing reasonable rectal safety 3. 
   data needed to approve vaginal microbicides. 
irma does not recommend halting or delaying the introduction of vaginal 
microbicides. irma believes the field should work diligently to ensure that 
gathering rectal safety data poses no delays to efficacy trials. Short rectal safety 
trials can be conducted in parallel to vaginal efficacy trials. 
irma, amag, amd and gcm have agreed to collaborate on the development of 
an “Advocate’s Brief ” focusing on rectal safety, and will collectively design and 
implement advocacy strategies connected with the statement in 2008.
The consensus statement is available at www.rectalmicrobicides.org.
3  IRMA in action: key activities   
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3.2 International survey on lubricants used for anal sex 
Over a period of 29 weeks, from February 14 to August 31, 2007, irma conducted an on-line survey on 
lubricants used for anal sex, which was hosted on www.surveymonkey.com. The purpose of the survey 
was to gather data on the types of lubricants people use, as well as preferred lube characteristics.
With 8,945 responses (nearly 78% were completed surveys) from 107 countries, this is the largest survey 
on anal sex ever conducted. Thanks to the work of volunteer translators from around the world, the 
survey was offered in six languages: English, French, German, Portuguese, Spanish and Turkish. It should 
be noted that despite having the survey translated in an additional four Indic and Dravidian languages 
(Hindi, Marathi, Telugu and Tamil), it was not possible to post the surveys for technical reasons.
The survey was promoted through various means. First, brief e-mail messages in various languages with 
three different target audiences (general, gay men/msm, and women) were sent periodically through 
various topical, regional and community listservs, including those focussed on hiv, microbicides, gay 
men’s health, women’s health, and sexual and reproductive health. Second, a number of websites posted 
information and links to the survey, including sites targeted to gay men and msm (e.g. LifeLube.org, 
Manhunt.net), barebacking, and rectal microbicides (i.e. irma). In addition, a number of individuals and 
organizations used the basic promotional messages to include notices in agency newsletters and websites. 
Finally, a number of specialized media outlets, both print and cyber, wrote articles about the survey. 
Many respondents were reached through old-fashioned word-of-mouth.
irma collaborated with colleagues at ucla  
who conducted the data analysis. 
The survey results provide valuable information 
relating to:
the lubricants more commonly used for anal sex;•	
how people use lubricants for anal sex;•	
preferred lubricant characteristics; and,•	
frequency of condom use during anal sex.•	
 
This information will be useful in helping 
advocates and researchers:
decide which lubricants should be prioritized for •	
safety testing; 
learn which lubricant characteristics are most •	
acceptable and should be considered in rectal 
microbicide development and packaging; 
understand which methods may improve lubricant •	
and condom access; 
gain insight into differences among regions, •	
genders and age; and, 
contemplate anal sex practices as they relate to •	
the sexual health of women and men in various 
regions.
32
Age: There was a fairly even distribution of age 
groups. Among those who indicated an age, 
25.4% of respondents were under 25, 21.6% were 
25-34, 30.1% were 35-44, and 22.8% were over 
45 years old. 
Information on all survey respondents
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Regions: Most respondents indicated they were 
from North America and Europe. Among those 
who indicated a country, 63.9% were from 
North America (u.s. and Canada), 26.9% were 
from Europe (29 countries), 3.9% were from 
Latin America and the Caribbean (27 countries), 
2.8% were from Asia (21 countries), 1.7% were 
from Oceania (Australia and New Zealand), 
0.6% were from Africa (18 countries), and 
0.2% were from the Middle East (8 countries). 
Gender: The vast majority of respondents were 
men, however over 900 women responded to 
the survey. Among those who indicated a gender, 
88.1% were men, 10.3% were women and 1.5% 
were transgendered.
Survey results among respondents who reported  
having anal sex in the past six months
The majority of survey respondents (70.1%, or 6,273 people) reported having anal sex within six months 
prior to the survey. The following data looks at this group.
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Language: Most respondents answered the English 
survey, although surveys completed in Turkish 
represented a significant proportion of the responses. 
Over one quarter of all responses was in languages 
other than English: English (71.8%), Turkish (19.8%), 
Spanish (4.2%), Portuguese (2%), German (1.2%), 
and French (1%). 
Demographics. There is a fairly even distribution of age groups across this cohort. However, the vast majority 
of respondents are North American males who responded in English. This is important to keep in mind 
when reviewing results from this cohort.
Language Age
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  (Re eptiv  A  nte ourse)     tiv  Ana  Int c ur e       Inse ve Ana  I e co rse(Insertive Anal Intercourse) ec pti l Int r u )
Condom use patterns. The patterns of condom use are quite similar when comparing receptive and insertive 
ai. Approximately 28% of respondents reported never using condoms, while approximately 35-37% of 
respondents always use condoms. Another 35-37% of people indicated either “rarely” or “often” using 
condoms. However, when asked about the frequency of changing condoms when sharing sex toys anally, 
Regions
Gender
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Lubes most commonly used.
Data analysis reveals that well over 100 different 
lubricants were named by respondents. Among 
these, the 15 most commonly named lubricants 
used for anal sex included, in alphabetical order: 
Astroglide (all types combined, including original), 
Crisco, Durex, Elbow Grease, Gun Oil, iD (all 
types combined, including Glide and Millennium), 
K-Y (all types combined), Liquid Silk, Pjur Eros, 
Probe, spit/saliva, Swiss Navy, Trojan, Vaseline and 
Wet (all types combined, including Wet original 
and Wet Platinum). The only notable differences 
among respondents who indicated they had anal 
sex as bottoms/receptive partners vs. tops/insertive 
partners, and using condoms vs. not using condoms 
were twofold: first, oil-based lubricants (Vaseline, 
Crisco) featured prominently among respondents 
who did not use condoms; second, respondents 
who did not use condoms were more likely to list 
spit/saliva as lubricant. 
a greater proportion of people reported never changing condoms between users (nearly 51%), compared 
to “always” (nearly 29%) or either option of “rarely” and “often” (approximately 20% combined). Since 
no information on the nature of the relationship with sexual partners was requested (casual vs. main 
partner, for example), or whether the hiv serostatus of partners was known, it is difficult to draw definitive 
conclusions about the levels of hiv risk that respondents faced.
Reasons for not using lubricant. 
Little more than a quarter of people who indicated they had engaged in anal sex in the past 6 months 
provided reasons why they did not use lube. The rest either indicated they did not have anal sex without 
lube, or they did not answer. The most common reasons given for not using lube were: used saliva instead 
(well over half of respondents), lube was not available (one-third), prefer dry sex, or used lubricated 
condoms. Overall, responses seem to indicate considerably high acceptability of lubes for anal sex, with 
“dislike lube” as the least common answer.  
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Lube characteristics: flavour, colour, smell. 
A very small percentage of respondents stated 
a preference for lubes that have a flavour 
(4.4%), colour (2%) or smell (6.6%).  
Lube consistency. 
Half of respondents prefer a liquid lube; 
over one third prefer a lube that is thick. 
Given these proportions, a rectal microbicide 
formulated as a lube would probably be most 
acceptable if available in both thick and more 
liquid-style formulations.
Lube dispensers. 
A variety of lube dispensers are preferred by 
respondents, with nearly half the respondents 
preferring a  dispenser with a pop-up lid or 
a pump, followed by tubes (over a quarter 
of respondents). One-fifth of respondents 
preferred single-use packets. 
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Conclusions. 
Most respondents who engage in anal sex do not always use condoms, but many people use lubricants, 
providing an excellent opportunity for a rectal microbicide formulated as a lube to provide protection. 
Most respondents report use of commercial lubricants, suggesting rectal microbicides that are similar to 
existing lube products will be acceptable. Indeed, a rectal microbicide formulated as a lube would probably 
have a high acceptability rate, especially if it has no flavour, colour or smell, and is available in both 
thick and liquid consistencies, and with the option of a water or silicone base. When testing lubricant 
products for rectal safety and testing candidate rectal microbicides for safety and efficacy, researchers 
should consider the implications of other substances (saliva, water, vaginal fluid) added to the product. 
Lubricant base. 
Both water-based and silicone-based 
lubes are preferred over oil-based 
lubes. Given these proportions, a rectal 
microbicide formulated as a lube would 
probably be most acceptable if available 
in both water-based and silicone-based 
formulations. 
Applying lube: Does it interrupt sex? 
Less than 6% of respondents felt that 
applying lube for anal sex interrupted 
sex and bothered them. The majority 
felt it did not interrupt sex (nearly 
53%) and even if they did feel lube 
application interrupted sex, it did not 
bother them (over 41%). These data 
indicate a very high acceptability rate 
for lube. 
Adding substances to lube. 
The majority of respondents indicated 
they added another substance to the 
lube they used for anal sex, including 
spit/saliva (55%), water (8.5%) or 
vaginal fluid (6.2%). When testing lubes 
for safety and rectal microbicides for 
both safety and efficacy, this behaviour 
should be taken into account.
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Next steps. 
irma will issue a full report of the survey data analysis by mid-2008. Sub-analysis 
will include a breakdown by age, gender, region and language. It will also include 
translation and analysis of qualitative data from all six languages, including a 
compilation of the most frequently named lubricants used for anal sex. These 
results will be disseminated to various target audiences (researchers, advocates, 
prevention educators, gay men, and women) using various means (fact sheets, 
teleconferences, published articles and the irma website as well as other web-based 
information).
Limitation of an on-line survey. 
As stated by Rhodes and colleagues: 
“The advantages of using the world wide web to collect behavioural data include rapid 
access to numerous potential respondents and previously hidden populations, respondent 
openness and full participation… and reduced research costs. Challenges identified include 
issues related to sampling and sample representativeness… and potential limitations 
resulting from the much cited “digital divide”, literacy, and disability… Justifiable concerns 
regarding the use of the world wide web in research exist, but… the world wide web 
may be the only research tool able to reach some previously hidden population subgroups. 
Furthermore, many of the criticisms of online data collection are common to other survey 
research methodologies.” 46
irma expresses sincere gratitude to the thousands of people who responded to 
the survey. 
3.3 Serving as a watchdog
In addition to promoting research to find a safe, effective and acceptable rectal 
microbicide, irma diligently works as watchdog to protect consumers against 
falsely marketed products. Working collaboratively in 2007, irma and gcm 
investigated the claims of a lubricant manufacturer in the United Kingdom 
called Kirklees Medical Limited. The company was making explicit claims on 
its website regarding the ability of its products to reduce the risk of sexually 
transmitted hiv infection with no proof of safety or efficacy. In an e-mail to irma 
from Kirklees Medical, a company representative stated that a Kirklees lubricant 
“is less than 50% effective against hiv in actual use between partners although it 
performed exceptionally well against other stis.”
gcm has maintained an Unproven Product Claims Watch for several years to 
raise awareness of products that are being presented to the public (without 
substantiating evidence) as effective microbicides and to advocate for the removal 
of such products from the market wherever possible. Knowing this, irma worked 
together with gcm, urging Kirklees either to provide peer-reviewed scientific 
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data supporting its anti-hiv/anti-sti claims or to cease making such statements. 
The Terrence Higgins Trust (tht), as a uK-based partner of both the gcm and 
irma, took the lead on generating this dialogue.
Once a complaint was registered by irma, gcm and tht with the uK’s Medical 
and Healthcare Regulatory Authority (mhra) in September 2007, Kirklees 
promptly removed some of the claims and misleading language from its website. 
However, as of press time, officials have yet to provide data demonstrating either 
(1) anti-hiv efficacy in vivo or (2) that long-term use of the product is safe over 
time (i.e. does not damage either vaginal or rectal epithelia in any way that might 
increase hiv risk).
The text of the letter that was submitted to mhra and other background materials 
are available at www.rectalmicrobicides.org, where updates on this matter are 
posted.
Caveat Rectum!
No product has yet been approved for use as an effective vaginal or rectal 
microbicide. Any product making such a claim should be reported immediately 
to regulators and advocacy organizations such as irma.
In order to raise awareness among advocates, irma and gcm have produced a 
fact sheet on the safety of sexual lubricants for vaginal and rectal use, which can 
be obtained from either group’s website, www.rectalmicrobicides.org or www.
global-campaign.org. 
irma continues to advocate and to work with researchers to promote rectal safety 
testing of sexual lubricants (see sections 2.12 and 3.2 for more information on 
these activities.
3.4 Key resources on the irma website
The irma website, www.rectalmicrobicides.org., is hosted and maintained by the 
aiDs Foundation of Chicago (afc). What follows are key resources most accessed 
by members and other visitors to the site.
Presentation slides and minutes from regular teleconferences.
irma, with the generosity of its organizational partners, hosts regular, free 
international teleconferences featuring speakers from around the world who are 
leading rectal microbicides research and advocacy efforts. All calls include a set of 
slides which participants can follow online. Minutes of the call are posted, and all 
materials are archived on the website.
Rectal Microbicides: Investments and Advocacy. 
This report, released by irma in April 2006 at the Microbicides 2006 conference, 
was the first document to specifically track rectal microbicide research 
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and development expenditures.  The report has recommendations for rectal 
microbicide advocates, researchers and funders. 
Consensus statement on rectal safety of vaginal microbicides. 
This statement calls upon the microbicide community to support rectal safety 
trials of vaginal microbicides which have progressed to Phase iii efficacy trials. 
The statement was endorsed by amag, amD, gcm, and irma.
Community education and awareness presentations. 
irma members regularly present on rectal microbicide advocacy in their 
communities and at local, national and international conferences. These 
presentations are highlighted on the site and other advocates are encouraged to 
use them as examples and templates that may be adapted for various audiences 
and contexts.
Resources on rectal microbicides. 
The website includes fact sheets, documents, reports, journal articles and links to 
other web-based resources on rectal microbicides.
Resources on other new prevention technologies. 
Information on prep, vaccines, male circumcision and vaginal microbicides, 
among other new prevention technologies, are highlighted with links.
Advocate and researcher bios. 
Rectal microbicide advocates and researchers from around the globe are regularly 
featured on the website. A short biography and a recent photo help connect 
members from distant locales, personalizing their experience and assisting irma 
in building and nurturing a virtual community.
News items and fresh resources. 
Notices on recent developments in the field and new informational resources are 
all prominently posted.
Contact. 
To sign up for the irma listserv or to communicate with irma for more information 
on how to become involved in rectal microbicides advocacy, internet users can 
utilize the contact portion of the website. 
.
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Irma’s over-arching goals are: 
To advocate for accelerated research, development and access to safe, effective and •	
acceptable rectal microbicides;
To promote rectal safety studies on all viable vaginal candidate microbicides;•	
To support, where appropriate, the research of other new prevention technologies, •	
such as male circumcision, vaccines and oral prevention (prep), and to promote 
existing prevention methods such as male and female condoms as part of a range 
of prevention options;
To serve as a central forum for exchange, debate, and networking on rectal •	
microbicides; and, 
To convene diverse perspectives and scientific disciplines to improve understanding •	
and action.
4.1 Ten rectal microbicide objectives to achieve by 2010
Over the next three years, from 2008-2010, irma will pursue the following ten 
objectives as a roadmap to achieving our goals:
Accelerated research 
Develop a document (1. Rectal Microbicide Research: Mind the Gap) which would 
provide an overview of key areas requiring urgent attention to move rectal 
microbicides research forward.
Recruit new researchers to the field by promoting the work of 2. irma, utilizing 
Rectal Microbicide Research: Mind the Gap and Less Silence, More Science as well as 
active engagement in scientific conferences. 
Implement advocacy strategies to increase funding for rectal microbicide 3. 
research five-fold, from u.s.$7 million/year in 2006 to a minimum of u.s.$35 
million/year in 2010.
Implement advocacy strategies to diversify funding sources for rectal microbicide 4. 
research, with a target of reaching 25% of global rectal microbicide research 
funding originating from non-u.s. government sources by 2010. Currently, 
more than 97% of rectal microbicide funding is from the u.s. government.
4 Looking forward: goals for Irma and the  rectal microbicides field
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Use the results of the lubricant survey to encourage the testing of additional 5. 
commercial lubricants for rectal safety, and disseminate the survey results to all 
vested audiences, including scientists engaging in acceptability and formulation 
work.
Advocate for increased research into global 6. ai incidence, prevalence and 
behavioural  contexts in which ai occurs.
Rectal safety of vaginal microbicides
Develop an 7. Advocates Brief on rectal safety of vaginal microbicides, and 
implement advocacy strategies connected with the Consensus statement on rectal 
safety of vaginal microbicides, with amag, amD and gcm. 
 
   
Participate in collaborative efforts and other prevention research networks 8. 
and listservs as means of ensuring visibility for rectal microbicides and to 
encourage greater integration and coordination of prevention research efforts. 
 
    
Increase 9. irma’s global reach, particularly in developing countries, by 
expanding means of participation in irma-related activities, including 
both electronic and non-electronic methods. This may include efforts to 
continue the development of the John Shaw Memorial Scholarship Fund 
which assists advocates in attending critical international conferences and 
exploring the possibility of developing a mentorship or buddy program in 
which more established advocates encourage and support new advocates. 
 
   
With key advocates, researchers, policy makers and funders, convene a forum for 10. 
 developing, monitoring, discussing and making decisions about the elements of 
 a Global Rectal Microbicide Development Plan.
4.2 Global rectal microbicide Development Plan
As the world’s first Phase I clinical trials evaluating the rectal safety of vaginal 
microbicides have gotten under way, the rectal microbicides field needs 
to consider the future course of research. The normal drug development 
pathway suggests that the next steps would be to move safe vaginal products 
into expanded rectal safety trials (Phase II), while concurrently developing 
rectal-specific formulations for Phase I safety trials, and moving those into 
expanded safety trials. A critical scientific question is determining whether a 
rectally safe vaginal microbicide would be effective in preventing, or at least 
reducing, hiv transmission associated with urai. To date, the animal data 
suggest that this might be possible, but these data are very preliminary and should 
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Other new prevention technologies
Mentor aspiring rectal microbicide advocates
Convene diverse perspectives
not be over-interpreted. The overall goal of course, would be to move towards 
large-scale Phase III rectal efficacy trials of either vaginal or rectal-specific 
formulations.
While this research pathway will obviously take several years to develop, several 
questions come to mind which must be addressed. Primarily, the field should 
consider whether this research pathway is actually feasible and if so, articulate a 
Global Rectal Microbicide Development Plan. 
First, who would fund such trials? 
As trials get larger, their visibility is heightened. Given the current rectal 
microbicides research funding context, it is uncertain whether or not the field 
can continue to rely almost exclusively on u.s. government funding. Diversifying 
the funding base for rectal microbicides research overall is absolutely critical, and 
may be a role that Europe and some foundations will be willing to play.
Second, how will this research process be coordinated?
The entire process of moving products through research phases will require a 
high level of coordination among key players. Comparing and coming to an 
agreement on research methodologies will be tremendously useful.
Third, where will the field locate research sites?
Large-scale efficacy trials of candidate rectal microbicides will need to be 
conducted in settings where there is a high incidence of hiv driven by uai. This 
will likely mean developing and building on trial sites to reach communities of 
gay men and other men who have sex with men, possibly in the u.s., Canada, 
Latin America, Western Europe, Australia, and South Africa. 
Fourth, what will be the broader prevention research and 
advocacy context within which these trials would occur?
It is likely that by the time candidate rectal microbicides reach large-scale 
trials, other new prevention technologies may already exist, creating significant 
challenges for trial design in terms of the prevention package offered for 
participants. At the same time, with challenges there are opportunities, and 
an intriguing Phase III study would be to compare oral prevention versus 
topical prevention. Advocates are crucial to maintaining the political climate 
for sustained research funding and community support and engagement for 
trials. Their support for trials of specific products and approaches within a 
broader context of prevention research may fluctuate.
A Global Rectal Microbicide Development Plan, and perhaps more importantly, 
a forum for developing, monitoring, discussing and making decisions about the 
elements of such a plan, would allow better alignment and coordination in the 
field and across new prevention technology research.
45
rectal microbicides advocacy…             
Developing safe, effective and acceptable 
rectal microbicides as quickly as possible 
for the women and men who need them 
globally requires the concerted efforts of 
advocates, researchers, policy makers and 
funders from all parts of the world.
              …Includes You
If you only have 5to10 minutes…
If you only have 30to60 minutes…
If you want to engage actively in 
shaping the rectal microbicide field…
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Visit the •	 irma website at www.rectalmicrobicides.org
Read one fact sheet or news item on rectal microbicides from the website•	
Sign up for the •	 irma listserv through the website 
Pass along our web address and contact information to another advocate, •	
researcher, policy maker or potential funder
Dial-in to one of •	 irma’s regular free teleconferences featuring world leaders in 
the field of rectal microbicide research and advocacy
Read some of the excellent resources on the website (•	 see section 3.4)
Download one of the prepared presentations and host a discussion with your •	
co-workers or other group
Talk to other members in your community about your interest in rectal •	
microbicides
Join one of •	 irma’s working groups to help us meet our objectives (see section 4.1)
Offer to join •	 irma’s Steering Committee
Become your community’s spokesperson for the research and development •	
of safe, effective and acceptable rectal microbicides by enlisting organizational 
support, conducting ongoing presentations and strategically engaging the media 
with support and direction from irma
Reach out to advocates, researchers, policy makers and funders and ask them to •	
join irma, to create policy that illuminates the importance of rectal microbicides, 
and to provide financial support for research and advocacy activities
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